Survodutide for treatment of obesity: Baseline characteristics of participants in a randomized, double‐blind, placebo‐controlled, phase 3 trial ( <scp>SYNCHRONIZE</scp> ™‐1)
SYNCHRONIZE-1 will determine the efficacy, safety, and tolerability of survodutide, a glucagon receptor/GLP-1 receptor dual agonist, for weight loss in a representative cohort of people with obesity without T2D.
Authors
- Carel Wynand le Roux (ORCID: https://orcid.org/0000-0001-5521-5445)
- Martina Brueckmann (ORCID: https://orcid.org/0000-0003-1215-0746)
- Elena Startseva (ORCID: https://orcid.org/0000-0002-9363-7056)
- Biykem Bozkurt (ORCID: https://orcid.org/0000-0002-6362-0253)
- Sean Wharton (ORCID: https://orcid.org/0000-0003-0111-1530)
- Gabriele Bleckert (ORCID: https://orcid.org/0000-0002-4341-9042)
- Elke Platz
- Lee M. Kaplan (ORCID: https://orcid.org/0000-0002-6301-2696)
- Isabel M. Kloer
- Samina Ajaz Hussain (ORCID: https://orcid.org/0009-0002-4849-0363)
Institutions
- University College Dublin (IE)
- Dartmouth College (US)
- Brigham and Women's Hospital (US)
- Boehringer Ingelheim (Germany) (DE)
- Harvard University (US)
- University of Ulster (GB)
- University of Mannheim (DE)
- Baylor College of Medicine (US)
- University of Toronto (CA)
- Heidelberg University (DE)
- McMaster University (CA)
Publication Details
- Journal
- Diabetes Obesity and Metabolism
- Published
- 2025-11-04
- DOI
- https://doi.org/10.1111/dom.70196
- Citations
- 1
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 1.29